BioSpace News Archive

Boston Children’s Hospital is the number one pediatric hospital in the nation for the seventh year in a row according to U.S. News & World Report’s 2020-21 Best Children’s Hospitals Honor Roll.

Erasca, a company whose mission is to erase cancer, today announced the expansion of its leadership team with the appointment of Bao Truong as vice president of regulatory affairs and David Luo as vice president of clinical research and operations. “We are delighted to continue attracti

Allows industry and academia access to cGMP-grade, NIH-registered AgeX ESI human pluripotent stem cells for development of cellular therapeutics AgeX ESI cell lines are among only a few pluripotent stem cell lines from which derived cell therapy candidates have been granted FDA IND clearance to begin human trials Pluristyx will manufacture, market, and distribute Ready-to-Use™ and Ready-to-Differentiate™ ESI stem cell lines vialed and frozen o

Celerion is proud to announce, for the fifth consecutive year, recognition of its early stage research development services across five categories in the 2020 CRO Leadership Awards sponsored by Life Science Leader and Industry Standard Research. Both small and large pharma respondents highlighted Celerion as a top performer in categories including Capabilities, Compatibility, Expertise, and Quality . Importantly,

Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50 collaboration to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19 (patients with SARS-CoV-2 infection). Monopar is a clinical-stage biopharmaceutical company and NorthStar is a commercial producer and supplier of medical radioisotopes. This collaboration combines NorthStar’s ex

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced it has entered into a securities purchase agreement,

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following upcoming investor conferences: 2020 BMO Prescription for Success Healthcare Conference on Tuesday, June 23, 2020 at 2:30 p.m. ET and; SVB Leerink CybeRx Series: 2 nd Annual CNS Forum on Wednesda

In a phase 1 study, RBT-6 was administered to study participants with moderate to severe chronic kidney disease (CKD) and showed an increase in expression of antioxidant proteins. These findings may help develop a pharmacologic stress test for determining antioxidant reserves in CKD and other medical conditions.

The Muscular Dystrophy Association announced its annual summer camp, which services more 3,000 children ages 8 to 17 living with neuromuscular diseases, will be held virtually in response to the COVID-19 pandemic.

Tyto Care names Sellers as VP Marketing to lead the company’s brand strategy in B2B and B2C efforts and Eitan as CFO to help expand business operations globally as demand for the unique telehealth solution surges